Indole Analogs as Novel Treatments for OCD

描述(申请人提供)：强迫症(OCD)是一种严重的精神疾病，影响着全世界数百万人。现有的治疗强迫症的方法疗效有限，可能会有令人担忧的副作用，而且往往需要长期治疗。发现一种治疗强迫症的新方法将具有相当大的科学和商业价值。药物治疗强迫症的一种方法是开发选择性5-HT2C受体激动剂，这是我们第一阶段工作的重点。在第二阶段，我们建议通过结构-活性关系(SAR)合成和生物评价程序来优化和进一步开发这些先导化合物。从这个项目中，我们的具体目标是发现一个或多个吲哚类似物，在我们的强迫症动物模型中显示出与批准的药物相当的疗效。这类化合物还将显示出良好的类药物特性。该项目的长期目标是发现一种治疗强迫症的新的、改进的药剂，该药剂可以获得许可并开发以获得最终的市场批准。

DESCRIPTION (provided by applicant): Obsessive Compulsive Disorder (OCD) is a serious mental illness that affects millions of people throughout the world. Existing therapies for OCD show limited efficacy, can possess troubling side effects, and often require long-term treatment. Discovery of a new treatment for OCD would have considerable scientific and commercial value. One approach to pharmacotherapy for OCD is the development of selective 5-HT2C receptor agonists, which was the focus of our Phase One work. In Phase Two, we propose to optimize and further develop these leads through a Structure-Activity Relationship (SAR) program of synthesis and biological evaluation. From this project we specifically aim to discover one or more indole analogs showing efficacy in our animal model for OCD that is comparable to approved medications. Such leads will also display favorable drug-like properties. The long term goal of this project is to discover a new, improved pharmaceutical agent for treatment of OCD that can be licensed and developed for ultimate market approval.